Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma

Hepatology. 2021 Jun;73(6):2591-2593. doi: 10.1002/hep.31706. Epub 2021 May 21.

Authors

Sharanya Maanasi Kalasekar¹, Ignacio Garrido-Laguna^{1

2}, Kimberley Jane Evason^{1

3}

Affiliations

¹ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
² Department of Internal Medicine, University of Utah, Salt Lake City, UT.
³ Department of Pathology, University of Utah, Salt Lake City, UT.

PMID: 33434363
DOI: 10.1002/hep.31706

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Biomarkers, Pharmacological / analysis
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / immunology
Carcinoma, Hepatocellular* / pathology
Clinical Trials as Topic
Drug Monitoring / methods
Humans
Immune Checkpoint Inhibitors / pharmacology*
Liver Neoplasms* / drug therapy
Liver Neoplasms* / immunology
Liver Neoplasms* / pathology
Progression-Free Survival
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*

Substances

Antineoplastic Agents, Immunological
Biomarkers, Pharmacological
Immune Checkpoint Inhibitors
Receptors, Vascular Endothelial Growth Factor

Grants and funding

R01CA222570/RG/CSR NIH HHS/United States